Mode of splenectomy and immunogenicity of meningococcal vaccination in patients with hereditary spherocytosis

British Journal of Surgery

Volumn 95, Issue 4, 2008, Pages 466-471

  Stoehr, G A ^a   Luecken, J ^a   Zielen, S ^b   Eber, S W ^c   Borrow, R ^d   Rose, M A ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MENCEVAXACWY; MENINGOCOCCAL C CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; PENICILLIN G; TETRAVALENT MENINGOCOCCAL POLYSACCHARIDE VACCINE; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE PREDISPOSITION; HAEMOPHILUS INFLUENZAE; HEREDITARY SPHEROCYTOSIS; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MENINGOCOCCEMIA; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERUM BACTERICIDAL ACTIVITY; SINGLE DRUG DOSE; SPLENECTOMY; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; ARTICLE; FEMALE; IMMUNOLOGY; MALE; MENINGOCOCCOSIS; METABOLISM; METHODOLOGY; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD;

ADOLESCENT; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SPHEROCYTOSIS, HEREDITARY; SPLENECTOMY;

EID: 41949095866     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.6008     Document Type: Conference Paper

References (27)

1. Eber SW, Armbrust R, Schröter W. Variable clinical severity of hereditary spherocytosis: relation to erythrocytic spectrin concentration, osmotic fragility, and autohemolysis. J Pediatr 1990; 117: 409-416.
2. Schwartz SI. Role of splenectomy in hematologic disorders. World J Surg 1996; 20: 1156-1159.
3. Stoehr GA, Stauffer UG, Eber SW. Near total splenectomy. A new technique for the management of hereditary spherocytosis. Ann Surg 2005; 241: 40-47.
4. Cherif H, Landgren O, Konradsen HB, Kalin M, Björkholm M. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine 2006; 24: 75-81.
5. Eber SW, Langendörfer CM, Ditzig M, Reinhardt D, Stohr G, Soldan W et al. Frequency of very late fatal sepsis after splenectomy for hereditary spherocytosis: impact of insufficient antibody response to pneumococcal infection. Ann Hematol 1999; 78: 524-528.
6. Molrine DC, Siber GR, Samra Y, Shevy DS, MacDonald K, Cieri R et al. Normal IgG and impaired IgM response to polysaccharide vaccines in asplenic patients. J Infect Dis 1999; 179: 513-517.
7. Leach A, Twumasi PA, Kumah S, Banya WS, Jaffar S, Forrest BD et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997; 175: 200-204.
8. Borrow R, Southern J, Andrews N, Peake N, Rahim R, Acuna M et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 2001; 19: 3043-3050.
9. Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000; 181: 761-764.
10. Balmer P, Falconer M, McDonald P, Andrews N, Fuller E, Riley C et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun 2004; 72: 332-337.
11. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344: 1378-1388.
12. Robert Koch Institut. STIKO - recommendations for the immunization of individuals at an increased risk for meningococcal infections. http://www.nki.de.
13. Rose MA, Schubert R, Strnad N, Zielen S. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin Diagn Lab Immunol 2005; 12: 1216-1222.
14. Stoehr GA, Rose MA, Eber SW, Heidemann K, Schubert R, Zielen S. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. Br J Haematol 2006; 132: 788-790.
15. Zhang Q, Lakshman R, Burkinshaw R, Choo S, Everard J, Akhtar S et al. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect Immun 2001; 69: 4337-4341.
16. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997; 4: 156-167.
17. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001; 69: 1568-1573.
18. Gheesling LL, Carlone GM, Pais LB, Holder PF, Maslanka SE, Plikaytis BD et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 1994; 32: 1475-1482.
19. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10: 780-786.
20. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen.J Exp Med 2003; 197: 939-945.
21. Robbins JB, Myerowitz L, Whisnant JK, Argaman M, Schneerson R, Handzel ZT et al. Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun 1972; 6: 651-656.
22. Vann WF, Liu TY, Robbins JB. Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect Immun 1976; 13: 1654-1662.
23. Guirguis N, Schneerson R, Bax A, Egan W, Robbins JB, Shiloach J et al. Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies. J Exp Med 1985; 162: 1837-1851.
24. Breukels MA, Zandvoort A, van den Dobbelsteen GP, van den Muijsenberg A, Lodewijk ME, Beurret M et al. Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides. Infect Immun 2001; 69: 7583-7587.
25. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994; 265: 1385-1387.
26. Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996; 174: 1360-1363.
27. McVernon J, Maclennan J, Buttery J, Oster P, Danzig L, Moxon ER. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children. Pediatr Infect Dis J 2002; 21: 747-753.